Induction of CD80 expression in low-grade B cell lymphoma--a potential immunotherapeutic target.
The CD80 antigen (B7) is expressed on activated B lymphocytes. It is thought to be important in eliciting a T cell response via its ligands CD28 and CTLA-4 when antigen is presented in the presence of the MHC-1 peptide. Low-grade B cell lymphomas analysed by flow cytometry express CD80 very poorly. However, when grown in vitro using the IL-4/anti-CD40 stromal cell culture system, following depletion of T and IgD-bearing cells, a monoclonal B cell expansion occurs. Cells harvested at days 10-13 express the antigen strongly, regardless of the histological subtype of lymphoma. Further investigation of CD80-mediated immune functions may be possible using this system as a basis for testing immunotherapy.
Shamash
J
J
ICRF Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
Davies
D C
DC
Salam
A
A
Rohatiner
A Z
AZ
Young
B D
BD
Lister
T A
TA
D018122:B7-1 Antigen / Q000378:metabolism*; D002469:Cell Separation; D006801:Humans; D016130:Immunophenotyping; D007167:Immunotherapy; D066298:In Vitro Techniques; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000628:therapy; D013997:Time Factors; D014407:Tumor Cells, Cultured
D018122:B7-1 Antigen